Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESA Meta-Analysis Underscores Survival Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Next step for FDA and Amgen on Aranesp: Finalizing REMS and agreeing on new trials.

You may also be interested in...



ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment, but stops short of some more restrictive REMS options such as patient registries or controlled distribution

ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment, but stops short of some more restrictive REMS options such as patient registries or controlled distribution

ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel